A Medicare patient sits in your clinic and asks about Wegovy or Foundayo. The conversation usually pivots on a single question. Can you offer a realistic path to coverage? For a long time, the answer was a reluctant no. The out-of-pocket costs were too high, the formulary restrictions were too tight, and the options for patients without type 2 diabetes were effectively zero unless they could pay the cash price. That reality shifted between April 21 and April 27, 2026. The Centers for Medicare and Medicaid Services extended the GLP-1 Bridge Model, sometimes called the Short-Term Bridge Program, through 2027. The program provides a structured $50 per month pathway for Medicare beneficiaries to access GLP-1 medications indicated for obesity. The formulary now includes the newly approved oral option, Foundayo. This changes the clinic conversation. It also changes your charting requirements. In this blog post, we will discuss what the GLP-1 Bridge Model requires, where Foundayo fits into your prescribing choices, and what specific documentation you must put in the chart to secure coverage for your patients today and protect their access when CMS re-evaluates the program in 2027.
What CMS actually announced and why it matters now
The [CMS announcement](https://www.cms.gov/newsroom/press-releases/coming-soon-cms-provide-50-monthly-access-glp-1-medications-medicare-beneficiaries) formalized an essential change in how we manage obesity in the Medicare population. CMS extended the GLP-1 Bridge Model through 2027. The original framing positioned this as a limited pilot. The recent update confirms a longer commitment and establishes a $50 per month access point for specific GLP-1 medications. This extension matters right now because it gives you a predictable framework for prescribing. [Recent reporting](https://www.usnews.com/news/health-news/articles/2026-04-27/cms-extends-medicares-short-term-bridge-program-for-glp-1-obesity-drug-coverage) highlights the timeline. The extension guarantees that the program will run through the end of 2027. The same reporting notes that CMS simultaneously shelved the BALANCE Model, which was expected to introduce broader payment redesign for obesity care. However, the shelving of BALANCE means the Bridge program is the only vehicle for obesity-medication coverage in this CMS cycle. You do not need to wait for a broader obesity-care reform package to pass. The rules are set for the next year and a half. The medications included on the formulary are defined. The cost structure is transparent to the patient. The initial pilot framing created hesitation. Clinics did not want to start patients on a medication pathway that might disappear in six months. The extension removes that immediate barrier. It gives you runway to titrate medications, assess clinical response, and document sustained weight loss over a meaningful period. This is a specific opening for a specific patient population. It requires exact adherence to the eligibility criteria. You must align your clinic processes with the CMS documentation requirements to use this program well.
The GLP-1 Bridge Model Framework
The GLP-1 Bridge Model provides Medicare beneficiaries with access to approved GLP-1 medications for obesity at a capped cost of $50 per month. The formulary includes Wegovy, Zepbound, and the newly approved Foundayo. This program targets the obesity indication specifically, which is an essential distinction. Patients with type 2 diabetes already have established coverage pathways for GLP-1 medications through standard Part D plans. The Bridge program fills the gap for patients who need metabolic and weight management but do not carry a diabetes diagnosis. The enrollment mechanism relies on clear clinical documentation. The patient must meet the defined eligibility criteria based on body mass index and related comorbidities. The process requires you to submit prior-authorization requests that clearly demonstrate the patient’s qualification under the obesity indication. The $50 monthly cap changes the adherence equation. Many of my patients have abandoned GLP-1 therapy because of fluctuating copays or coverage gaps. A predictable $50 cost allows patients to commit to the long-term treatment plan necessary for meaningful weight reduction. The inclusion of multiple agents on the formulary gives you clinical choices. You can select the medication based on the patient’s specific metabolic profile and preferences. Wegovy offers established cardiovascular risk-reduction data, while Zepbound provides a higher magnitude of weight loss and Foundayo offers an oral alternative to weekly injections for patients who refuse needles. You must remember that this is a bridge. It connects the current state of restricted coverage to a future where obesity might be recognized differently in standard Medicare structures. Your participation requires understanding the rules of this specific bridge.
Foundayo Positioning within the Clinical Formulary
Foundayo is the trade name for orforglipron, an oral non-peptide GLP-1 receptor agonist. The [FDA approved Foundayo](https://www.statnews.com/2026/04/01/eli-lilly-obesity-pill-approved-orforglipron-foundayo/) on April 1, 2026, and the approval marked an essential shift in obesity management. Foundayo is the first oral GLP-1 approved specifically for weight management. Its inclusion on the Bridge formulary is the headline for many clinics. You likely have patients who refuse injectable medications. This needle phobia is a real clinical barrier. Foundayo removes the barrier and allows you to offer a highly effective therapy to a broader segment of your patient panel. The [labeling details](https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-foundayotm-orforglipron-only-glp-1-pill) confirm its role as a daily oral medication. This changes the patient-education requirement. You trade the injection training for a discussion about daily adherence and gastrointestinal tolerability. We also have emerging data on how Foundayo performs when patients switch from injectable therapies. The [ATTAIN-MAINTAIN trial](https://www.pharmacytimes.com/view/orforglipron-shows-strong-weight-maintenance-in-phase-3-attain-maintain-trial) provides useful context. Patients switching from semaglutide to orforglipron saw a 5 percent weight regain, while patients switching from tirzepatide experienced a 20 percent regain. The [peer-reviewed ATTAIN-2 data](https://www.nejm.org/doi/abs/10.1056/NEJMoa2505669) further details the efficacy profile. This maintenance data informs your sequencing decisions. You might start a patient on an injectable for maximum initial weight loss and then transition them to Foundayo for long-term maintenance. The Bridge program accommodates this kind of sequencing by including all three options on the formulary. The oral option simply expands your toolkit for patients who need a different delivery mechanism to stay compliant.
Documentation: BMI ≥30 or ≥27 with weight-related comorbidity
The success of your prescription relies entirely on your chart notes. The Bridge program follows the standard FDA-labeled adult obesity indication. You must prove the patient meets these criteria. The primary requirement is a BMI of 30 or higher. If the BMI is between 27 and 29.9, the patient must have at least one weight-related comorbid condition, such as hypertension, type 2 diabetes, or dyslipidemia. You must capture the BMI value accurately at the index visit. Do not rely on patient-reported height and weight. Measure it in the clinic and document it clearly. When relying on the lower BMI threshold, your documentation must be explicit. You must list the specific comorbidity diagnosis codes in the assessment and plan. You cannot simply state the patient is overweight. You must connect the weight to the active management of their hypertension or dyslipidemia. You also need to document a previous attempt at lifestyle intervention. A simple note stating “diet and exercise counseled” is rarely sufficient. You should detail the specific dietary changes discussed and the recommended physical-activity targets. If the patient has participated in a structured weight-loss program, note the dates and outcomes. A contraindication screen is mandatory. You must document a negative personal and family history of medullary thyroid carcinoma. You must also document a negative history of Multiple Endocrine Neoplasia syndrome type 2. A single sentence confirming this review protects the patient and satisfies the authorization requirements. Your chart should read like a checklist for the reviewer. State the BMI. List the comorbidities. Detail the lifestyle counseling. Confirm the absence of contraindications. Select the medication. This precise approach minimizes prior-authorization denials.
Who is NOT covered, and what to tell those patients
The Bridge program has strict boundaries. You will have patients who ask for these medications but do not qualify. Clear communication is essential to manage expectations and maintain the therapeutic relationship. Patients with a diagnosis of type 2 diabetes are not covered under the Bridge program for obesity management. These patients must access GLP-1 medications through their standard Part D coverage. The clinical conversation here involves explaining that their diabetes diagnosis dictates a different coverage pathway. You will need to work through their specific Part D formulary rather than the Bridge program rules. Patients with a BMI between 25 and 26.9 do not qualify. This applies even if they have severe metabolic derangements. The FDA indication is a hard line. You must explain that the medication is not approved or covered for their current weight class. The conversation should pivot back to aggressive lifestyle management and to optimizing the treatment of their specific metabolic conditions. Patients with active or recent malignancies may fall into a gray area depending on the specific cancer. The decision to prescribe is off-label and often outside the scope of Bridge coverage. You must explain the lack of safety data and the resulting lack of program coverage. When a patient does not qualify, you must document the reason clearly. Note the specific criterion they failed to meet. This creates a record of the conversation and protects you if the patient later claims you refused to treat them. The discussion is never easy, but grounding it in the rigid program rules removes the personal element from the denial.
Projected Impact of the Failed BALANCE Legislation
The shelving of the BALANCE Model simplifies your immediate planning. BALANCE was intended to test broader payment models for obesity care. It would have introduced complex quality metrics and value-based payment structures. If BALANCE had proceeded, clinics would be preparing for a significant administrative shift. You would need to track patient outcomes differently. You would need to report specific metabolic markers to secure your reimbursement. The focus would have moved from simple medication access to wider program management. The delay of BALANCE means the fee-for-service structure remains dominant for now. The Bridge program provides the medication access without the immediate requirement to overhaul your clinic’s billing and reporting infrastructure. However, this delay gives you time. You can begin building the internal processes needed for value-based obesity care without the pressure of an active CMS pilot. You can refine your documentation, establish standardized follow-up protocols, and track your own outcomes. When CMS eventually introduces a broader reform model, your clinic will be prepared. For now, the focus remains on the specific documentation required for the Bridge program.
The 2027 cliff: what your documentation today determines
The Bridge program is an extension, not a permanent benefit. It runs through 2027. CMS will reassess the program based on the data collected during this period. The chart entries you make today are the evidence base CMS will use for that reassessment. You must document like an auditor is reading your notes. Every follow-up visit must include an updated weight and a recalculated BMI. You must document the percentage of weight lost since the start of therapy. Subjective improvements are helpful, but objective data is mandatory. Document the reduction in blood pressure. Note the improvement in lipid panels. Track the decrease in hemoglobin A1c, even in non-diabetic patients. These metrics demonstrate the clinical value of the medication beyond simple weight reduction. If a patient is not losing weight, document the reason. Are they struggling with adherence? Are they experiencing intolerable side effects? Did they lose access to the medication temporarily? Clear documentation of these challenges helps CMS understand the real-world limitations of the therapy. Yes, your charting habits directly influence the future of obesity coverage in Medicare. If CMS reviews the data in 2027 and finds poor adherence and minimal weight loss, the program will likely end. If they find consistent documentation of significant metabolic improvement, the program may evolve into a permanent benefit. You are writing the data set right now.
What this is NOT
The Bridge program has specific limitations. You must understand what it does not cover to avoid frustration and wasted administrative time. This program is not a permanent CMS benefit. The extension through 2027 is a defined window. You cannot promise patients lifetime access at the $50 price point. This program is not a substitute for lifestyle intervention. The FDA indications require concurrent diet and exercise modification. Your chart must reflect this ongoing effort. The Bridge program does not cover diabetes-indicated GLP-1 medications, such as Ozempic or Mounjaro. Those medications remain under the standard Part D processes for patients with type 2 diabetes. This program does not cover compounded GLP-1 products. A recent FDA delisting rule removed the pathway for compounded versions of these specific medications. You must prescribe the branded products listed on the formulary. Do not attempt to use the Bridge program to secure coverage for pharmacy-compounded alternatives.
Conclusion
Undoubtedly, the extension of the GLP-1 Bridge Model gives you a practical tool for managing obesity in your Medicare panel. You can now offer a realistic path to effective therapy. Identify your eligible patients based on the strict BMI and comorbidity criteria. Document the qualifying indication clearly in your initial assessment. Choose the most appropriate product from the formulary, such as Foundayo for patients who require an oral option, Zepbound for those who need maximum weight loss, or Wegovy for patients with established cardiovascular disease. Chart every visit with the 2027 reassessment in mind. Document the objective improvements in weight and metabolic markers. Your precision in the clinic today protects your patients’ access to these medications tomorrow. If you build these documentation habits now, you can rest assured that the chart you hand to a CMS reviewer in 2027 will tell a clean story about clinical value. This is a narrow window, and your documentation is the key to keeping it open.
Licensed physician and clinical AI specialist. Founder and Editor-in-Chief of ZayedMD, a physician-led medical publication covering clinical AI, neurology, metabolic health, and evidence-based patient guidance.
